MarketPeel
Insider Trading Intelligence
Pricing
…
TD

Thomas James Doyle

KURA
SVP, FINANCE & ACCOUNTING · KURA ONCOLOGY, INC. · CIK 0001910331
FILING MIX · LIFETIME45%/55%
BUYS
13
SELLS
16
TOTAL VALUE
$253.5K
COMPANIES
1
ACTIVE SINCE
Feb 2022
HOLDINGS NOW
150,083
AVG SELL PX
$10.12
TRADE KIND
SHOWING 29 / 29
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
15 backtested trades · 8 horizons · 20 pending
Forward-return performance of every backtestable P/S trade by Thomas James Doyle, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d15+46.67%+5.53%-0.13%+5.65%+8.06%—
14d15+40.00%+2.04%+0.49%+1.56%+7.21%—
30d15+46.67%+1.98%-0.42%+2.40%+3.02%—
60d15+73.33%-1.93%-2.94%+1.02%+0.21%—
90d15+46.67%-5.59%-0.10%-5.49%+3.70%—
180d15(4 pending)+72.73%-11.32%+8.14%-19.47%-25.95%—
1y15(6 pending)+33.33%-10.79%+19.93%-30.72%-11.91%—
2y15(10 pending)+100.00%-50.87%+47.05%-97.92%-100.58%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
KURA · 150,083 shares · as of Jan 27, 2026
038,07776,155114,232152,3092023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 13 buys / 16 sellsCOVERAGE · 17 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
881$8.46$7.5K145,167Jan 27, 2026Jan 27, 2026 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
2,226$8.46$18.8K146,048Jan 27, 2026Jan 27, 2026 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
1,114$8.46$9.4K148,969Jan 27, 2026Jan 27, 2026 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
695$8.46$5.9K148,274Jan 27, 2026Jan 27, 2026 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
2,226$8.46$18.8K150,083Jan 27, 2026Jan 27, 2026 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
42,500——42,500Jan 2, 2026Jan 6, 2026 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
21,250——152,309Jan 2, 2026Jan 6, 2026 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
4,539$11.18$50.7K130,257Nov 14, 2025Nov 14, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
24,967——134,796Nov 13, 2025Nov 14, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
4,541$8.94$40.6K109,829Sep 29, 2025Sep 29, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
24,966——114,370Sep 27, 2025Sep 29, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
1,122$7.87$8.8K88,193Jan 28, 2025Jan 28, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
699$7.87$5.5K89,315Jan 28, 2025Jan 28, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
887$7.87$7.0K90,014Jan 28, 2025Jan 28, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
2,241$7.87$17.6K90,901Jan 28, 2025Jan 28, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
21,250——71,892Jan 2, 2025Jan 6, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
21,250——93,142Jan 2, 2025Jan 6, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
42,500——42,500Jan 2, 2025Jan 6, 2025 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
594$17.80$10.6K49,817Jan 29, 2024Jan 31, 2024 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
761$17.80$13.5K49,056Jan 29, 2024Jan 31, 2024 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
963$17.80$17.1K48,093Jan 29, 2024Jan 31, 2024 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
21,250——50,411Jan 2, 2024Jan 4, 2024 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
42,500——42,500Jan 2, 2024Jan 4, 2024 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
10,625——27,466Feb 16, 2023Feb 21, 2023 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
63,750——63,750Feb 16, 2023Feb 21, 2023 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
682$13.89$9.5K17,707Jan 27, 2023Jan 31, 2023 ↗View →
KURA
KURA ONCOLOGY, INC.
SALE
SVP, Finance & Accounting
866$13.89$12.0K16,841Jan 27, 2023Jan 31, 2023 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
39,281——39,281Feb 7, 2022Feb 9, 2022 ↗View →
KURA
KURA ONCOLOGY, INC.
PURCHASEGRANT
Stock grant
8,390——15,000Feb 7, 2022Feb 9, 2022 ↗View →
Other insiders · KURA
Loading peer insiders…
About this filer
CIK 0001910331
ROLE
SVP, Finance & Accounting
PRIMARY
KURA
COMPANIES
1
ACTIVE SINCE
Feb 2022
MARKETPEEL · /INSIDER/0001910331DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback